September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
Clearance of Aflibercept Following Intravitreal Injection in a Rat Model
Author Affiliations & Notes
  • Ruti Sella
    Department of Ophthalmology, Rabin Medical Center, Petach-Tikva, Israel
    Sackler School of Medicine, Tel-Aviv University, Tel Aviv, Israel
  • Orly Gal-Or
    Department of Ophthalmology, Rabin Medical Center, Petach-Tikva, Israel
  • Assaf Dotan
    Department of Ophthalmology, Rabin Medical Center, Petach-Tikva, Israel
  • Mor Dachbash
    Laboratory of Eye Research, Felsentstein Medical Research Center, Rabin Medical Center, Petach-Tikva, Israel
  • Yael Nisgav
    Laboratory of Eye Research, Felsentstein Medical Research Center, Rabin Medical Center, Petach-Tikva, Israel
  • Dov Weinberger
    Department of Ophthalmology, Rabin Medical Center, Petach-Tikva, Israel
    Sackler School of Medicine, Tel-Aviv University, Tel Aviv, Israel
  • Rita Ehrlich
    Department of Ophthalmology, Rabin Medical Center, Petach-Tikva, Israel
    Sackler School of Medicine, Tel-Aviv University, Tel Aviv, Israel
  • Tami Livnat
    Sackler School of Medicine, Tel-Aviv University, Tel Aviv, Israel
    Laboratory of Eye Research, Felsentstein Medical Research Center, Rabin Medical Center, Petach-Tikva, Israel
  • Footnotes
    Commercial Relationships   Ruti Sella, None; Orly Gal-Or, None; Assaf Dotan, None; Mor Dachbash, None; Yael Nisgav, None; Dov Weinberger, None; Rita Ehrlich, None; Tami Livnat, None
  • Footnotes
    Support  Travel Grant, ISVER (Israel Society for Vision & Eye Research)
Investigative Ophthalmology & Visual Science September 2016, Vol.57, 3326. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Ruti Sella, Orly Gal-Or, Assaf Dotan, Mor Dachbash, Yael Nisgav, Dov Weinberger, Rita Ehrlich, Tami Livnat; Clearance of Aflibercept Following Intravitreal Injection in a Rat Model. Invest. Ophthalmol. Vis. Sci. 2016;57(12):3326.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Aflibercept is known as a potent anti vascular endothelial growth factor (anti-VEGF), though little is known regarding its clearance mechanism following intravitreal injection to the eye. Our purpose was to characterize the localization and clearance of intravitreally injected Aflibercept in the eye in a rat model.

Methods : Choroidal neovascularization (CNV) was induced by diode laser photocoagulation on the right eye of 8 Brown Norway rats.
3µl Aflibercept (25mg/ml) was injected intravitreally on day 3 from CNV induction. Immediately after Aflibercept injection and 3,6,24 and 48 hours later, animals were euthanized and eyes were enucleated for immunofluorescence staining. Donkey anti-human IgG labeled with Alexa Fluor® 488 was used for Aflibercept immunoreactivity detection. Untreated eyes were used as negative control. Anti CD31 antibody was used as a marker for schlemm's canal's endothelial cells. Intensity of the immunofluorescence staining was analyzed qualitatively.

Results : Aflibercept immunoreactivity was detected in the cornea, iridocorneal angle, and the retina immediately after injection, and declined in a decremented manner within the following hours.
Forty eight hours from the injection no Aflibercept staining was detected in the structures mentioned above.

Conclusions : Our study demonstrated the immediate accumulation of intravitreally injected Aflibercept in retina, cornea and iridocorneal angle and its presence there at least for 24 hours.
Clearance of Aflibercept molecules from the eye through the iridocorneal angle and retina were shown to take place within 48 hours.

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×